We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+43.13%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$99.8M
AUM Growth
+$21.6M
Cap. Flow
-$5.44M
Cap. Flow %
-5.45%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
3
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IMDZ
Immune Design Corp.
IMDZ
+$5.41M
2
URGN icon
UroGen Pharma
URGN
+$35K
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$302

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$2.13B
$45.7M 45.77%
1,449,745
-1,584
-0.1% -$35K
AGRX
2
DELISTED
Agile Therapeutics
AGRX
$22.6M 22.62%
2,531
– –
MRSN
3
DELISTED
Mersana Therapeutics
MRSN
$16.5M 16.55%
38,228
– –
IMDZ
4
DELISTED
Immune Design Corp.
IMDZ
$14.6M 14.65%
1,413,280
-549,440
-28% -$5.41M
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$404K 0.4%
6,777
-5
-0.1% -$302

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q3 2017 Portfolio in Review

As of Q3 2017, ProQuest Associates IV held 5 positions worth $99.8M, up 28% from $78.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $5.44M in Q3 2017, reducing 3 holdings. Its largest reduction was Immune Design Corp., cutting an estimated $5.41M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q3 2017 reduction was Immune Design Corp., cutting an estimated $5.41M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $99.8M portfolio in Q3 2017.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q3 2017.
  • ProQuest Associates IV's portfolio value rose 28% quarter-over-quarter to $99.8M.

Based on ProQuest Associates IV's 13F filing for Q3 2017, filed 14 Nov 2017.